Document Detail

Cost-effectiveness of rituximab in follicular lymphoma.
MedLine Citation:
PMID:  23140274     Owner:  NLM     Status:  Publisher    
In advanced follicular lymphoma, rituximab is currently used with chemotherapy as induction therapy, and as maintenance monotherapy following induction in previously untreated patients and treatment-experienced relapsed/refractory patients. Herein, the authors characterize the clinical effectiveness, safety and cost-effectiveness of rituximab in follicular lymphoma, based on the literature review. Rituximab has a favorable safety profile and has been shown to improve progression-free survival, with some evidence of improvements to overall survival, particularly for relapsed/refractory patients. Rituximab has consistently been found to have a favorable economic profile, with cost per quality-adjusted life year falling within standard thresholds for cost-effectiveness. Challenges in cost-effectiveness analysis include the fact that life expectancy for patients with follicular lymphoma exceeds the period of available follow-up data and that treatment pathways are more complex than the model structures frequently used in oncology models. As data accrue and more complex models are developed, the cost-effectiveness of rituximab can be more accurately assessed.
Karissa M Johnston; Corneliu Bolbocean; Joseph Connors; Stuart Peacock
Related Documents :
16619984 - Aggressive fibromatosis--impact of prognostic variables on management.
23825744 - The challenge of prognostic markers in pleural mesothelioma.
24720384 - Assessing prognostic documentation and accuracy among palliative care clinicians.
22987974 - Novel and bone-targeted agents for crpc.
6621234 - Postoperative radiotherapy for persistent tumor at the surgical margin in head and neck...
17502194 - Outcomes of primary liver cancer in children: an appraisal of experience.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-11
Journal Detail:
Title:  Expert review of pharmacoeconomics & outcomes research     Volume:  -     ISSN:  1744-8379     ISO Abbreviation:  Expert Rev Pharmacoecon Outcomes Res     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101132257     Medline TA:  Expert Rev Pharmacoecon Outcomes Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Attention deficit hyperactivity disorder, tic disorder, and allergy: is there a link? A nationwide p...
Next Document:  Synaptotagmin-like protein 4 and rab8 interact and increase dense granule release in platelets.